Celltrion closes in on COVID-19 antibody market after trial successSouth Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first Share XCelltrion closes in on COVID-19 antibody market after trial successhttps://pharmaphorum.com/news/celltrion-closes-in-on-covid-19-antibody-market-after-trial-success/
Celltrion buys drug portfolio from Takeda, ventures into chronic diseasesSouth Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Share XCelltrion buys drug portfolio from Takeda, ventures into chronic diseaseshttps://pharmaphorum.com/news/celltrion-ventures-into-chronic-diseases-with-takeda-portfolio-buy/
Celltrion trials infliximab biosimilar in recovering COVID-19 patientsSouth Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery Share XCelltrion trials infliximab biosimilar in recovering COVID-19 patientshttps://pharmaphorum.com/news/celltrion-trials-infliximab-biosimilar-in-recovering-covid-19-patients/
Celltrion to develop coronavirus antibody and fast testSouth Korea’s Celltrion has joined the many pharma companies fighting the COVID-19 coronavirus outbreak, saying it is working Share XCelltrion to develop coronavirus antibody and fast testhttps://pharmaphorum.com/news/celltrion-antibody-and-fast-test/
Celltrion plans to launch a biosimilar each year for next decadeThere are plenty of pharma companies outlining their strategies for the new decade this week at the JP Share XCelltrion plans to launch a biosimilar each year for next decadehttps://pharmaphorum.com/news/celltrion-plans-to-launch-a-biosimilar-each-year-for-next-decade/
Celltrion gears up for subcutaneous infliximab launch in EuropeCelltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe Share XCelltrion gears up for subcutaneous infliximab launch in Europehttps://pharmaphorum.com/views-analysis-market-access/celltrion-gears-up-for-subcutaneous-infliximab-launch-in-europe/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Celltrion/Teva’s Herceptin biosimilar approved in USThe FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor Share XCelltrion/Teva’s Herceptin biosimilar approved in UShttps://pharmaphorum.com/news/celltrion-tevas-herceptin-biosimilar-approved-in-us/
Sandoz axes filing of US Rituxan biosimilarSandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved Share XSandoz axes filing of US Rituxan biosimilarhttps://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/
